Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 12/20 | 0.49 |
| ▸ | HTR1A | P08908 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD5 | P21918 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PER2 | O15055 | 1/20 | 0.43 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28298254 | 0.83 | HTR7 (0.54) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL14663959 | 0.83 | HTR7 (0.49) | HTR7HTR1AHPGDDRD2DRD5 | |
| SCHEMBL2510154 | 0.82 | MEN1 (0.59) | DRD2DRD3DRD4POLB | |
| SCHEMBL28279911 | 0.80 | HTR7 (0.53) | HTR7HTR1AHPGDDRD2DRD5 | |
| SCHEMBL27430141 | 0.80 | HTR7 (0.47) | HTR7HTR1AHPGDDRD2DRD5 | |
| SCHEMBL8083943 | 0.78 | ALDH1A1 (0.39) | HTR7HTR1ADRD2DRD5DRD3 | |
| SCHEMBL25865291 | 0.78 | HDAC1 (0.39) | DRD2DRD5DRD3 | |
| SCHEMBL26621469 | 0.78 | ATAD2 (0.49) | HTR7HPGDDRD2DRD5DRD3 | |
| SCHEMBL26024964 | 0.78 | NR1I2 (0.51) | DRD2DRD5DRD3DRD4NOTUM | |
| SCHEMBL5999408 | 0.77 | HTR7 (0.57) | HTR7HTR1ADRD2DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020031816-A1 | METHOD OF INHIBITION OF HUMAN GLYCOGEN PHOSPHORYLASE | PFIZER PRODUCTS INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0978279-A1 | Inhibitors of human glycogen phosphorylase | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5998463-A | Glycogen phosphorylase inhibitors | PFIZER INC (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | HTR7 4660/4885HTR1A 4465/4885HPGD 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.